Goldman Sachs’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Goldman Sachs’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-242,071	Closed	-$1.61M	–	5916
2023 Q3	$1.61M	Sell	242,071 -717,388	-75%	-$5.96M	﹤0.01%	3926
2023 Q2	$8.69M	Sell	959,459 -50,434	-5%	-$445K	﹤0.01%	2588
2023 Q1	$7.34M	Buy	1,009,893 +768,242	+318%	+$5.7M	﹤0.01%	2699
2022 Q4	$1.76M	Buy	241,651 +62,965	+35%	+$467K	﹤0.01%	4034
2022 Q3	$1.38M	Sell	178,686 -220,111	-55%	-$1.87M	﹤0.01%	4296
2022 Q2	$2.71M	Buy	398,797 +312,692	+363%	+$2.39M	﹤0.01%	3771
2022 Q1	$686K	Sell	86,105 -45,431	-35%	-$288K	﹤0.01%	5122
2021 Q4	$737K	Buy	+131,536	New	+$987K	﹤0.01%	5088

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Goldman Sachs's PNT Position: Q4 2023 in Review

Goldman Sachs sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 242,071 shares — an estimated $1.61M sold.

Goldman Sachs first reported a position in PNT in Q4 2021 and held it in 8 quarters. The position peaked at $8.69M in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Goldman Sachs reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Goldman Sachs sold 242,071 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $1.61M.
Goldman Sachs first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Goldman Sachs's POINT Biopharma Global Inc. Common Stock position peaked at $8.69M in Q2 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Goldman Sachs's 13F filing for Q4 2023, filed 13 Feb 2024.